Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 1,262 shares at $2.72 ($3K) on 2013-02-27, disclosed to the SEC on 2013-02-28.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.71 | 500 | $1K | 39.5% |
| 2 | $2.72 | 535 | $1K | 42.4% |
| 3 | $2.75 | 227 | $624 | 18.2% |
| Total | $2.72 avg | 1,262 | $3K | 100% |
| Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-20 | $23K | — | Filing → |